| pubmed-article:3510823 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3510823 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3510823 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:3510823 | lifeskim:mentions | umls-concept:C0028005 | lld:lifeskim |
| pubmed-article:3510823 | lifeskim:mentions | umls-concept:C0028066 | lld:lifeskim |
| pubmed-article:3510823 | lifeskim:mentions | umls-concept:C0340288 | lld:lifeskim |
| pubmed-article:3510823 | lifeskim:mentions | umls-concept:C0699826 | lld:lifeskim |
| pubmed-article:3510823 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:3510823 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3510823 | pubmed:dateCreated | 1986-3-10 | lld:pubmed |
| pubmed-article:3510823 | pubmed:abstractText | Forty-one patients were studied in a randomized double-blind placebo-controlled crossover trial to compare the antianginal actions of nicardipine 30 mg thrice daily and nifedipine 10 mg thrice daily. Efficacy was assessed using objective criteria from computer-assisted multistage graded exercise testing, performed after a two-week placebo run-in period and at the end of each four-week active treatment period. Thirty-seven patients completed both legs of the crossover trial. The mean (+/- standard error of the mean) baseline exercise time to development of angina was 6.7 +/- 0.4 min and this increased to 9.5 +/- 0.6 min on nicardipine (p less than 0.001) and 9.5 +/- 0.5 min on nifedipine (p less than 0.001 vs baseline; NS vs nicardipine). Both drugs significantly prolonged the time to the development of 1mm ST segment depression. The baseline resting heart rate of 83 +/- 2 beats/min increased to 87 +/- 3 beats/min during nicardipine (p less than 0.05) and remained unaltered at 83 +/- 2 beats/min during nifedipine therapy (p = NS vs baseline and p less than 0.02 vs nicardipine). Similarly, both drugs increased significantly the maximal heart rate at peak exercise. One patient was lost to follow-up during the placebo run-in period and four patients (two each on nicardipine and nifedipine) were withdrawn due to adverse effects. Our results indicate that nicardipine is comparable in efficacy to nifedipine and has a similar adverse effect profile and can also be considered a useful therapeutic agent for the treatment of chronic stable angina pectoris. | lld:pubmed |
| pubmed-article:3510823 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3510823 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3510823 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3510823 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3510823 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3510823 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3510823 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3510823 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:3510823 | pubmed:issn | 0012-3692 | lld:pubmed |
| pubmed-article:3510823 | pubmed:author | pubmed-author:RafteryE BEB | lld:pubmed |
| pubmed-article:3510823 | pubmed:author | pubmed-author:O'HaraM JMJ | lld:pubmed |
| pubmed-article:3510823 | pubmed:author | pubmed-author:KhurmiN SNS | lld:pubmed |
| pubmed-article:3510823 | pubmed:author | pubmed-author:BowlesM JMJ | lld:pubmed |
| pubmed-article:3510823 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3510823 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:3510823 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3510823 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3510823 | pubmed:pagination | 260-5 | lld:pubmed |
| pubmed-article:3510823 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:meshHeading | pubmed-meshheading:3510823-... | lld:pubmed |
| pubmed-article:3510823 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3510823 | pubmed:articleTitle | Randomized double-blind placebo-controlled comparison of nicardipine and nifedipine in patients with chronic stable angina pectoris. | lld:pubmed |
| pubmed-article:3510823 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3510823 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3510823 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:3510823 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3510823 | lld:pubmed |
